PharmaBioTechHealthcareLegalScience

Biosimilars And Complex Medicines For All With RNA Therapeutics' Sarfaraz Niazi, Ph.D.

Life Science Connect
Life Science Connect•Apr 13, 2026

Why It Matters

Clearer biosimilar regulations and affordable mRNA therapies can dramatically lower drug costs and expand global patient access, reshaping the biotech industry's business model.

Key Takeaways

  • •Pioneered bio‑similar development before FDA had clear guidelines.
  • •Helped embed the BPCIA into the ACA, creating biosimilar pathway.
  • •Encountered tiered analytics hurdles, highlighting strict FDA comparability standards.
  • •Advocates affordable mRNA bio‑similar therapies for global patient access.
  • •Leveraged VOA radio to demystify science, policy, and philosophy.

Summary

The interview with Dr. Sarfaraz Niazi, CEO of RNA Therapeutics, explores his decades‑long journey from academia to industry and his pivotal role in shaping the biosimilar landscape. He recounts early work on biological drugs before the FDA had a formal framework, his involvement in drafting the Biologics Price Competition and Innovation Act (BPCIA) that was folded into the Affordable Care Act, and the launch of his mRNA bio‑similar programs. Key insights include the absence of clear regulatory guidance in the late 1990s, the adoption of tier‑based analytical requirements that forced developers to meet stringent comparability metrics, and the political navigation required to secure legislative support—illustrated by his direct correspondence with then‑Senator Barack Obama. Niazi also highlights the challenges of aligning patent exclusivity periods, noting the shift from an eight‑year to a twelve‑year exclusivity window. Notable anecdotes feature his meeting with Obama in Chicago, a memorable FDA advisory panel where a big‑pharma representative warned that biosimilars would “kill everybody,” and his eight‑year stint hosting a Voice of America radio program that blended science, philosophy, and public education for millions of listeners. The discussion underscores the critical need for transparent, science‑based regulatory pathways to bring complex biologics and emerging mRNA biosimilars to market affordably. Niazi’s advocacy signals that clearer guidelines and policy reforms could accelerate access to life‑saving therapies worldwide, benefiting both innovators and patients.

Original Description

On this week's episode of the Business of Biotech, we speak with Dr. Sarfaraz Niazi, Ph.D., about how biosimilar regulations have taken shape, from early FDA uncertainty to citizen petitions, lawsuits, and guideline changes. Dr. Niazi offers a behind the scene look at the way FDA policy gets made, and unmade, and his own role in key regulatory changes, and legislation such as the Biologics Price Competition and Innovations Act (BPCIA), and the Inflation Reduction Act (IRA). We also discuss Dr. Niazi's current company, RNA Therapeutics, and his quest to make new drug modalities accessible to patients around the world.
Access this and hundreds of episodes of the Business of Biotech videocast at lifescienceleader.com
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:

Comments

Want to join the conversation?

Loading comments...